Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
5 mill bid is starting to move up !!
Hold on boys and girls lets see what happens here !!
HUGE bid 5.5 million shares... whoo hoo !!
PLEASE show me where i quoted ANYTHING? lmao
You show up ONLY after the fda came out w/ a letter.. the fda ALWAYS will come back to w/something to justify their existence... it happens ALL the time..PLEASE PROVE me WRONG !!
My exact question to YOU is.. wait for it.. because i wasn't clear the first time i asked the question.. PLEASE prove and or provide your alleged allegations regarding the china deal.. " 236T568 Member Level Tuesday, 02/20/18 01:37:39 PM Post # 814 of 823
CRYO and the China sham transactions - how scam companies do it!"
As i asked, PLEASE provide PROOF for YOUR allegations!!
How hard is that to understand or interpret what i asked? LMAO !!
You keep posting BS but cant prove it...LMAO !!
Still waiting for you to prove your alleged allegation against CRYO
Still waiting for the proof about what you keep posting !!
PLEASE provide proof
nice volume today !!
will CRYO break .69 today?
CRYO moving back up into the mid .60s ...
(IMO) OMHE has been silent ... IMO, i think they have GREAT things going on behind the scene that we will all hear about in the near future...
Autisticallycompetent,
for some reason it wont let me reply to you but yes, i thought i saw them last week...i could be wrong..
Funny YOU keep POSTING the SAME THING over and OVER.. Give it a rest...
American CryoStem Corporation As of December 31, 2017 and September 30, 2017
http://ih.advfn.com/p.php?pid=nmona&article=76715502
YAWN !!
hoping we BREAK out of the .65 range soon...
Lets go CRYO !!
Thank goodness for Les and the truth !!
I know several pet owners who use CBD for their pets. People now days will spend anything to help out their pets !!
MCIG should be green next week too !!
someone trying really hard to keep the ask .0288 and not going higher
nice buys on the ask !!
lets hope it get back up to the .75-1.00 range here in the near future !!
You are posting OLD news.. lol
Spot on wwj, bid now is .57 ask is now .58.... all companies who deal w/ FDA always get something from them...its fumy after all the GOOD things going on with this company a RANDOM person shows up to beat the stock up... kind of odd in my opinion !!
CRYO looks like its starting to move up... nice bid !!
nice share on the short chart !!
Les,
Thank you for updating all us shareholders w/ great information !!
BIG bid today... lets hope it starts to move up into the .60s soon !!
hey goodibag,
glad to see you back !!
yes they are !!CRYO killing it and look ot reduce cost in the future !!
i agree wwj.... some cheap shares down here w/ the numbers they came out with !!
********ICYMI -American Cryostem Corporation 2017 Year End Update^^^^^^^
http://www.otcmarkets.com/stock/CRYO/news
American Cryostem Corporation 2017 Year End Update
EATONTOWN, NJ / ACCESSWIRE / January 16, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding the Company's Year ending September 30, 2017;
- Total Revenue increased to $1,865,364 in Fiscal 2017 versus $593,938 in Fiscal 2016, an increase of 214%,
- Accounts Receivable increased to $171,860 in Fiscal 2017 from $65,335 in Fiscal 2016, an increase of 163%
- International Revenue increased to $496,456 in Fiscal 2017 from $199,011 in Fiscal 2016 an increase of 149%
- Tissue Storage and Processing increased to $1,364,373 in Fiscal 2017 from $394,927, in Fiscal 2016 an increase of 245%.
- Short term liabilities increased to $1,922,100 in Fiscal 2017 from $1,272,991 in Fiscal 2016, an increase of 51% mainly attributed to the reclassification of certain long term debt to short term
- Long term debt decreased from $1,265,684 to $108,651 a decrease of 91.4% also mainly attributable to the reclassification of certain long term debt to short term
- Cost of Sales increased to $554,514 in Fiscal 2017 from $294,006 in Fiscal 2016, related to the increase in processing and sales. Cost of Sales as a percentage of Tissue Storage, Processing and Product Sales was reduced from 58% to 38%.
- Professional fees decreased (principally legal and accounting) to $72,990 in Fiscal 2017 from $169,207 in Fiscal 2016, a decrease of 131%
- Research and Development decreased from $114,453 in Fiscal 2016 to $87,210 in Fiscal 2017, a decrease of 24%, attributed to the completion of certain research projects
"American CryoStem's 2017 results reflect our continued focus on revenue production and cost control in all of the revenue segments of the company. We will continue to expand our tissue processing marketing efforts and the further development of our products and standardization of our laboratory operations," stated Anthony Dudzinski, COO, he continued "we will also continue to seek cost savings through our ongoing efforts to minimize laboratory expenses by optimizing processing efficiencies and potential outsourcing opportunities."
John S. Arnone, CEO stated, "We are very optimistic about the state of the Regenerative Medicine Industry globally as we enter 2018. We have seen a steady increase of new international companies seeking to license our turn-key stem cell collect-process-store program and associated Intellectual Property utilizing our proprietary products and services to create processing and storage facilities." Arnone further stated, "In 2018 we look forward to expanding our US based physician network, patient adipose tissue and stem cell storages, increasing our global laboratory licensing program and continuing an organization-wide initiative to create new products and optimize our internal quality systems and processes."
In 2018, management intends to continue its focus on increasing revenue, reducing costs, expanding our international licensing program and assisting our affiliate(s), Baoxin Asia Pacific Biotechnology Co, LTD (Baoxin) with establishing two new laboratory and therapy centers in Beijing and Shanghai to cover the regenerative medicine needs of China. Our plan includes assisting our partners with establishing a physician education facility in China to promote the use of ATGRAFT as a natural cosmetic filler, and as a preferred material to the artificial fillers currently used in cosmetic applications. We also plan to finalize and submit an Investigational New Drug (IND) application for our ATCellTM product to the U.S. FDA to support our cellular platform and regenerative medicine services.
About American CryoStem Corporation:
American CryoStem Corporation (PINK SHEETS: CRYO) was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, Shenzhen, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology that supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physician's networks and research organizations who purchase tissue collection, processing, and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that works in conjunction with our patented (non-animal) medium lines. The Company's R&D efforts are focused on discovering, developing and commercializing ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.
The company assumes no obligation to update any information contained herein.
SOURCE: American CryoStem Corporation
© Copyright © 2018 Accesswire. All rights reserved.
GREAT info Peterbelt and shortorlong !!
it should be getting closer to CRYO releasing the 10k if i counted the days correctly.
Kraken,
what is your best guess for omhe to break the .04s and move into the .05s? Would like to hear / see some news in the very near future !
nice DD Peterbelt !!
Will we see .35 this week? i think sooooo !! MCIG GREEN !!
if I've calculated the days correct after CRYO filed NT10k on Dec 29th, they should be out this Friday or Monday of next week... here's hoping the fins look GREAT for the year !!
We consider the agency our partners with the goal of ensuring healthcare safety. In alignment with this commitment, we have made it an organization-wide priority initiative to continually optimize quality systems and processes, including completing and submitting an Investigational New Drug (IND) application.
OLD NEWS ...nice try !!
NEWS out from CRYO regarding FDA
American CryoStem Statement on the Receipt of a Warning Letter from FDA
EATONTOWN, NJ / ACCESSWIRE / January 8, 2018 / American CryoStem Corporation (PINK SHEETS: CRYO)) today issued a statement acknowledging that it has received a warning letter issued by the U.S. Food & Drug Administration (FDA) dated January 3, 2018 relating to its adipose derived stem cell product and its production facilities. This action follows the earlier inspections of the Company's New Jersey facility by the agency between July 17 and July 26, 2017.
CRYO CEO, John Arnone commented, "We take any comments or suggestions by the U.S. FDA very seriously. We have initiated the changes in response to the FDA's initial observations dated July 26, 2017. With regard to quality and cGMP compliance matters, we stand by our commitment to fully comply with the cGMP quality standards at our facility. We will further respond with an updated comprehensive plan to address FDA's updated observations contained in the letter received January 3, 2018, within the stipulated time-frame of 15 business days. We will actively engage with the agency to resolve these issues and continue to improve our quality systems and processes, as an organization-wide priority."
We consider the agency our partners with the goal of ensuring healthcare safety. In alignment with this commitment, we have made it an organization-wide priority initiative to continually optimize quality systems and processes, including completing and submitting an Investigational New Drug (IND) application.
About American CryoStem Corporation: American CryoStem Corporation (PINK SHEETS: CRYO) was founded in 2008, and has evolved to become a biotechnology pioneer, standardizing adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The Company operates a state-of-art, FDA-registered, clinical laboratory in New Jersey and licensed laboratories in Hong Kong, Shenzhen, China and Tokyo, Japan, operating on our proprietary platform, dedicated to the collection, processing, bio-banking, culturing and differentiation of adipose tissue (fat) and adipose-derived stem cells (ADSCs) for current or future use in regenerative medicine. CRYO maintains a strategic portfolio of intellectual property (IP) that surrounds our proprietary technology that supports a growing pipeline of stem cell applications and biologic products. We are leveraging our proprietary platform and a developed product portfolio to create a domestic and global footprint of licensed laboratory affiliates, physician's networks and research organizations who purchase tissue collection, processing, and storage consumables from our Company. Our laboratory stem cell bank/line products are characterized adult human Mesenchymal Stem Cell (MSC's) derived from adipose tissue that works in conjunction with our patented (non-animal) medium lines. The Company's R&D efforts are focused on discovering, developing and commercializing ADSC therapies by utilizing our standardized collection-processing-storage methodology and laboratory products combined with synergistic technologies to create jointly developed regenerative medicine applications and intellectual property.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency/severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.
The company assumes no obligation to update any information contained herein.
SOURCE: American CryoStem Corporation
© Copyright © 2018 Accesswire. All rights reserved.